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Background
　Appropriate analgesia is important for postopera-
tive pain relief, the prevention of postoperative 
nausea and vomiting (PONV) and early postoperative 
recovery1). Droperidol has strong antiemetic activity 
and is administrated for prophylaxis of PONV2). An 
intravenous route of administration is generaly 
recommended for droperidol3). The intravenous (IV) 
injection of droperidol bolus at the end of the surgery 
is recommended for prophylactic antiemetic therapy2). 
Also, the repeated IV infusion of an antiemetic mixed 
with an opioid has been performed in the setting of 
patient-controled analgesia (PCA)4), 5).
　In contrast to IV administration, the continuous 
epidural injection (CEPI) of droperidol has been used 
along with epidural block for postoperative pain relief 
in Japan6)-8). It was reported that droperidol given by 
CEPI was more efective than placebo6)-8).
　However, the advantage of the epidural injection 
(EPI) of droperidol compared with IV administration 
is not clear. Also, a comparison between EPI and IV 
injection of a droperidol bolus showed that the IV 
route was superior to the EPI route for prophylaxis of 
PONV9). We doubted the eficacy of the CEPI of 
droperidol in Japan. The continuous IV infusion 
(CIVI) of droperidol or its repeated IV infusion in the 
setting of PCA may be more efective than CEPI. 
However, this has not yet been investigated.
　We planed this study to evaluate the eficacy of the 
CEPI of droperidol. We hypothesized that the CIVI of 
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Background : The continuous epidural injection (CEPI) of droperidol has been used in Japan for 
prophylaxis of postoperative nausea and vomiting (PONV). To evaluate the CEPI of droperidol, we 
compared the eficacy of droperidol given by the CEPI with given by the continuous intravenous 
injection (CIVI).
Methods : The patients scheduled for gynecological surgery accompanied by epidural analgesia were 
randomly alocated to an CEPI or CIVI group. In the CEPI group, droperidol (1.25 mg) was injected 
epiduraly at the time of suturing folowed a CEPI of droperidol (5 mg in 48ml) at 1 ml/h.  In the CIVI 
group, droperidol (1.25 mg) was injected intravenously at the time of suturing folowed a CIVI of 
droperidol (5 mg in 48ml) at 1 ml/h. The incidence and severity of PONV were evaluated in both groups.
Results : 103 patients in the CEPI group and 102 patients in the CIVI group were included. The 
incidence of PONV in the first 24 hours (37.9% in the CEPI group and 32.4% in the CIVI group) and the 
severity of nausea during the first 72 hours were not diferent significantly between the two groups.
Conclusion : The eficacy of droperidol was not diferent comparing CEPI with CIVI.
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droperidol would be superior to CEPI for prophylaxis 
of PONV. To test our hypothesis, we compared the 
two routes of administration in gynecologic patients, 




　This study was approved by the Ethics Committee 
of Yamagata University, and written informed 
consent was obtained from al patients. From 
September 2005 to May 2008, female patients were 
enroled at Yamagata University Hospital (Yamagata, 
Japan). The patients ranged in age from 20~69 years 
and were in the American Society of Anesthesiologists 
Physical Status (ASA-PS) category 1 or 2. Al patients 
were scheduled for elective gynecological abdominal 
surgery under general anesthesia accompanied by 
epidural analgesia. Patients were excluded based on 
the folowing criteria: impossible to communicate 
suficiently in Japanese; the use of opioids, 
antipsychotic drugs, antidepressants, adrenocorti-
costeroids, antiemetics or antihistamines; pregnancy; 
diseases of the central nervous system; or a history of 
convulsions. A 12-lead ECG was obtained in al 
patients in the month before surgery. Patients with a 
QTc >0.470 seconds or ventricular premature 
contractions >6 beats/minutes were excluded.
 
Protocol
　The patients were randomly alocated to an CEPI 
or CIVI group. The medical staf was blinded to their 
randomization assignment except for the anesthesi-
ologist in charge of the case. Anesthetic management 
was the same in each group as folows. Patients were 
premedicated oraly with ranitidine hydrochloride 
(150 mg) two hours before arrival at the operating 
room (OR). If necessary, 5~10 mg diazepam was 
added oraly one hour before arrival. On arrival at the 
OR, a 3-lead ECG, pulse oximeter and noninvasive 
blood pressure monitor (MP70; Royal Philips 
Electronics, Amsterdam, Netherlands) were attached 
to each patient. If invasive blood pressure monitoring 
was necessary, cannulation of the radial artery was 
performed after induction of general anesthesia. IV 
injection of acetated Ringer’s solution was also 
started before the induction of anesthesia. An 
epidural catheter was inserted at the interspace 
between Th9 and L2. An anesthesiologist who has 
two or more years of experience managed the 
insertion of the epidural catheter. The catheter was 
aspirated and 2 ml of 0.75% ropivacaine was injected 
into the catheter to verify appropriate placement of 
the catheter tip. If no adverse reactions occurred with 
these two tests, general anesthesia was induced with 
IV thiopental sodium (3~4 mg/kg) after inhalation of 
oxygen (O2, 5 L/min) for several minutes. When 
patients lost consciousness, inhalation of sevoflurane 
was started with an FiO2 of 100%. Vecuronium 
bromide (0.1 mg/kg) was injected intravenously, and 
tracheal intubation was performed. After tracheal 
intubation was completed, mechanical ventilation 
was started with an FiO2 of 45-60%. Anesthesia was 
maintained  using  sevoflurane  (1~3%)  and  IV 
fentanyl, and epidural block was performed with 
ropivacaine. The volume of fluid infusion was 
adjusted according to the condition of each patient. If 
necessary, a plasma expander or packed red cels were 
administered. When systolic blood pressure (SBP) 
was <80 mmHg, patients were given IV ephedrine 
hydrochloride (4~8 mg) or methoxamine hydrochlo-
ride (1 mg).  The need for these vasoconstrictors was 
based on the judgment of the anesthesiologist in 
charge. Al patients were given an epidural injection 
of morphine (2 mg) in 5 ml of saline at the beginning 
of the operation and 10 ml of 0.23% ropivacaine at the 
time of suturing of the operative wound. After the end 
of the operation, inhalation of sevoflurane was 
discontinued.  When  spontaneous  respiration 
appeared, atropine sulfate (1 mg) and neostigmine (2 
mg) were injected intravenously to reverse the efects 
of vecuronium bromide. The patients were extubated 
when they woke up and resumed spontaneous 
respiration. After extubation, the patients left the OR 
when they were stable based on the judgment of the 
anesthesiologist in charge. After leaving the OR, the 
folowing parameters were monitored: ECG, blood 
pressure, heart rate, body temperature, oxygen 
saturation (pulse oximeter), and clinical status.
　Droperidol was administered at the time of 
suturing of the operative wound. In the CEPI group, 
droperidol (1.25 mg) in 5 ml of saline was injected 
epiduraly at the time of suturing. In addition, a CEPI 
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of morphine (4 mg), 1% lidocaine (46 ml) and 
droperidol (5 mg in 2 ml) was started at a rate of 1 
ml/h at the time the patient left the OR. This group 
also received a CIVI of saline (48 ml) at 1 ml/h at the 
same time as the CEPI. In the CIVI group, droperidol 
(1.25 mg) in 5 ml of saline was injected intravenously 
at the time of suturing. In addition, a CEPI of 
morphine (4 mg), 1% lidocaine (46 ml) and saline (2 
ml) was started at a rate of 1 ml/h at the time the 
patient left the OR. This group also received a CIVI of 
droperidol (5 mg in 2 ml) and saline (46 ml) at 1 ml/h 
starting at the same time as the CEPI. The CEPI and 
CIVI were continued for at least 24 hours in both 
groups. A disposable infusion pump (Coopdech 
Syrinjector®, Daiken-iki, Osaka, Japan) was used for 
both the CEPI and CIVI. The contents of the 
disposable pumps could not be identified based on 
appearance. After emergence from anesthesia, the 
patients were supplemented with an intramuscular 
injection of pentazocine (15 mg) or anal administra-
tion of diclofenac sodium (25 mg) for postoperative 
pain, and IV injection of metoclopramide (10 mg) for 
severe PONV. On the first postoperative day, the 
patients started drinking water and taking oral 
loxoprofen sodium hydrate (180 mg/day) for pain 
relief.  Standing and walking were also attempted. A 
physician, who was blinded to the randomization 
assignment, visited each patient at 6 hours, 24 hours 
and 72 hours after leaving the OR. This physician 
evaluated the folowing parameters: severity of 
nausea, pain (at rest and with movement) and 
pruritus; incidence of vomiting; and amount of 
supplementary pentazocine, diclofenac sodium, and 
metoclopramide from 0～6, 6～24 and 24～72 hours 
after leaving the OR.  Other complications from 0～
72 hours after leaving the OR were also evaluated. 
For the evaluation of nausea, pain (at rest and with 
movement) and pruritus, the patients were asked to 
respond with one of the folowing five words: “nai” 
(none), “sukoshi” (little), “tyuugurai” (moderate), 
“tsuyoi” (severe), or “taerarenai” (unbearable). The 
results provided a verbal-rating score (VRS) for the 
severity of each symptom. The evaluation of vomiting, 
amount of supplementary drugs used and other 
complications were based on postoperative records 
and the patient interview. The primary endpoint was 
the incidence of PONV in the first 24 hours after the 
operation. It was defined as the fraction of patients 
that vomited or felt little, moderate, severe or 
unbearable nausea from 0～24 hours after leaving the 
OR. Secondary endpoints were the severity of nausea 
and the incidence of vomiting from 0～6, 6～24 and 24
～72 hours after leaving the OR.
Statistical analysis
　We considered that the incidence of PONV in the 
first 24 hours after the operation would be 40% in the 
CEPI group based on unpublished data and 20% in 
the IV group based on repeated IV infusion in the 
setting of PCA10),11). Therefore, we estimated that a 
sample size >92 was needed to detect a ≥20% 
diference in the incidence of PONV between the two 
groups (assuming a two-sided α error of 0.05 and 
80% power)12).
　Data values are expressed as means±SD, medians 
[minimum-maximum] or numbers and percentages.  
Statistical comparisons between the two groups were 
performed using an unpaired t-test or a chi-square 
test for patient characteristics, vomiting and the 
incidence of PONV.  The severity of nausea, pain, and 
pruritus and the amount of supplementary drugs 
were compared between groups using a Mann-
Whitney U test. Al analyses were performed with 
PASW® statistics 18 (SPSS, Chicago, USA). P values 
< 0.05 were considered significant.
Results
　Among the 293 patients enroled, 71 patients were 
excluded because of the exclusion criteria or because 
they declined to participate in the study. After 
randomization, 17 patients were excluded for the 
folowing reasons: eight patients failed to complete 
the protocol, three patients developed acute ilness 
(one thyroid crisis, one severe bradycardia and one 
dural puncture), and six patients had unscheduled 
bowel resection during the surgery that changed the 
postoperative management.  Therefore, 205 patients 
were included in the final analysis, 103 in the CEPI 
group and 102 in the CIVI group.
　The patient characteristics are shown in Table 1. 
There were no significant diferences between the two 
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　　　　　Table 1. Patient characteristics
Values are means ± SD or numbers (percentages). There were no significant differences between the groups.
Hy, hysterectomy; Ad, adnexectomy; Om, omentectomy; PL, pelvic lymphadenectomy; PaL, para-aortic 
lymphadenectomy, CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
groups. The numbers of patients with a PONV risk 
factor were not significantly diferent between the 
two groups (Table 1).
　The incidence of PONV in the first 24 hours after 
the operation was 37.9% in the CEPI group and 
32.4% in the CIVI group. There was no significant 
diference between the two groups (p= 0.496).
　The PONV results are shown in Table 2. The 
respective fraction of patients that replied none, little, 
moderate, severe or unbearable for the severity of 
postoperative nausea from 0～6, 6～24 and 24～72 
hours after leaving the OR was not significantly 
diferent between the two groups. Likewise, the 
incidence of postoperative vomiting during each of the 
three time periods was not significantly diferent 
between the two groups. The amount of supplemen-
Table 2. The severity of PONV during the first 72 hours after leaving the operating room. 
CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
Values are numbers (percentages) or medians [minimum-maximum]. There were no significant 
differences between the two groups. 
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tary metoclopramide used in each group from 0～6, 6
～24 and 24～72 hours after leaving the OR ranged 
from 0～30 mg. The median value was 0 for al time 
periods in each group, and there were no significant 
diferences between the two groups.
　For postoperative pain (at rest and with move-
ment), the respective fractions of patients that replied 
none, little, moderate, severe or unbearable from 0～
6, 6～24 and 24～72 hours after leaving the OR were 
not significantly diferent between the two groups 
(Table 3). The amount of supplementary pentazocine 
and diclofenac sodium used from 0～6, 6～24 and 24～
72 hours after leaving the OR in both groups ranged 
from 0～30 mg and 0～75 mg, respectively. The 
median value was 0 for both drugs during al three 
time periods in both groups, and there were no 
significant diferences between the two groups (Table 
3). For pruritus, the respective fraction of patients 
that replied none, little, moderate, severe or 
unbearable was not significantly diferent between 
the two groups (Table 4).
　There were a few other complications that occurred 
from 0～72 hours after leaving the OR. Nine patients 
(8.7%) in the CEPI group and seven patients (6.9%) in 
the  CIVI  group  developed  hypotension  (SBP 
<80mmHg). Al of these patients recovered with only 
fluid therapy. The incidence of hypotension was not 
significantly diferent between the two groups. In 
Table 4. The severity of pruritus during the first 72 hours after leaving the operating room. 
CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
Values are numbers (percentages). There were no significant differences between the two groups.
Table 3. The severity of pain during the first 72 hours after leaving the operating room. 
CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
Values are numbers (percentages) or medians [minimum-maximum]. There were no significant 
differences between the two groups. 
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addition, one transient ischemic attack, one asthmatic 
attack and two cases of ileus occurred in the CIVI 
group. Those patients recovered without invasive 
treatment. One patient in the CEPI group developed 
restlessness and an extrapyramidal reaction was 
suspected. The patient recovered after the end of the 
droperidol injection. There were no other major 
complications in either group.
Discussion
　This study compared CEPI with CIVI of droperidol 
for the prophylaxis of PONV in patients undergoing 
gynecologic surgery with continuous epidural analge-
sia. The incidence of PONV, postoperative pain (at 
rest and with movement), pruritus, and other 
complications was not significantly diferent between 
the two groups. The eficacy of droperidol was not 
diferent comparing CEPI with CIVI.  There were no 
advantages of CEPI over CIVI.
　In this study, the dosage of droperidol given by CIVI 
for the prophylaxis of PONV was based on the dosage 
recommend for IV PCA (a single bolus of 0.625~1.25 
mg during anesthesia folowed by an infusion of 
0.05~0.1 mg per mg of morphine, as required)5).  
Klahsen, et al. reported that the PCA with a 1 mg IV 
bolus of droperidol folowed by an infusion of 0.04 mg 
per mg of morphine resulted in 3.9±1.12 mg of 
droperidol administrated in the first 24 hours 
postoperatiely13).  On the other hand, the dosage of 
droperidol administered by CEPI for the prophylaxis 
of PONV was reported to be 2.5-5 mg per day6)-9), and 
this was similar to the dosage for CIVI. Therefore, we 
administrated the same total dose to the patients in 
the CEPI and CIVI groups to alow a valid comparison 
between the groups. The dosage of droperidol given to 
both groups was 3.75 mg in the first 24 hours 
postoperatively, and this should have been suficient 
to prevent PONV.
　Recently, the risk factors for PONV in adults were 
reported. Gan et al. reviewed the risk factors for 
PONV in adults14). They indicated that the wel-
established risk factors for PONV include female 
gender, nonsmoking status, history of motion sickness 
or PONV, intraoperative and postoperative opioid 
administration, prolonged duration of surgery and 
the use of volatile anesthetics or neostigmine (>2.5 
mg)14). These risk factors also apply to Japanese 
patients15). The presence of multiple risk factors also 
increases the incidence of PONV16). Because of the 
detailed analysis of risk factors for PONV in our 
study, we believe that our results may be more 
accurate than the results of previous studies.
　Droperidol has antiemetic activity due to the 
antagonism of dopamine (D2) receptors at the 
chemoreceptor trigger zone (CTZ) in the brain stem 
(area postrema)17),18). Droperidol administered by the 
epidural route may be absorbed from the epidural 
space into blood or cerebrospinal fluid (CSF). 
Droperidol absorbed into blood is delivered to the 
CTZ via the systemic circulation, whereas droperidol 
absorbed into CSF is delivered to the CTZ via the CSF 
circulation8), 9).
　However, it is uncertain which route of delivery of 
droperidol to the CTZ is most important. Nakata et 
al.8) reported that delivery via the CSF circulation was 
more important than delivery via the systemic 
circulation, because the blood concentration of 
droperidol after bolus epidural injection was only half 
of that after bolus IV injection19), and the antiemetic 
efect of droperidol was similar comparing bolus IV 
injection with CEPI8). In contrast, Sanansilp et al.9) 
indicated that absorption into blood was more 
important, because droperidol is nonpolar and not 
easily absorbed into CSF.  In our study, the incidence 
of PONV was not diferent comparing CEPI and CIVI 
of droperidol. Since droperidol may enhance the efect 
of analgesics11) and inhibit epidural morphine-induced 
pruritus20), we expected analgesic and antipruritic 
efects in the CEPI group. However, these efects were 
not observed. Therefore, we speculate that the 
antiemetic efect of droperidol administered by CEPI 
was due to absorption into the systemic circulation, 
similar to that obtained by CIVI. Namely, the 
pharmacokinetics of droperidol given by CEPI are 
similar to the pharmacokinetics of droperidol given by 
continuous intramuscular injection.
　In a previous study, Sanansilp et al.9) compared 
epidural injection with IV injection of a single 
droperidol bolus. They found that IV injection was 
superior to epidural injection for the prophylaxis of 
PONV and for antipruritic activity9). To account for 
intravenous versus epidural droperidol
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the diference between their results and our results, 
we speculate that the duration of action of droperidol 
given by bolus epidural injection is shorter than that 
of droperidol given by bolus IV injection, because the 
blood concentration of droperidol after bolus epidural 
injection was only half of that observed after bolus IV 
injection19). However, CEPI should keep the blood 
concentration of droperidol high enough to prevent 
PONV.  A dose-response relationship has never been 
established  for  the  prophylaxis  of  PONV  by 
droperidol in the setting of PCA4).
　This study has several limitations. First, this study 
was performed at a single institution. Second, the 
CIVI of droperidol is not used in routine clinical 
practice for the prophylaxis of PONV. Although the 
same dose of IV droperidol was administered as that 
used in the setting of PCA, droperidol in PCA is not 
constant IV injection. Third, we did not measure any 
blood concentrations of droperidol in this study.
conclusion
　The eficacy of droperidol was not diferent 
comparing CEPI with CIVI. The CEPI of droperidol 
was a useful prophylaxis of PONV for the patients 
undergoing continuous epidural analgesia.
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